Safety and efficacy of a feed additive consisting of \textit{Limosilactobacillus reuteri} (formerly \textit{Lactobacillus reuteri}) DSM 32264 as a feed additive for cats (NBF Lanes s.r.l.)

EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Vasileios Bampidis, Giovanna Azimonti, Maria de Lourdes Bastos, Henrik Christensen, Birgit Dusemund, Mojca Fačsmon Durjava, Maryline Koub, Marta López-Alonso, Secundino López Puente, Francesca Marcon, Baltasar Mayo, Alena Pechová, Mariana Petkova, Fernando Ramos, Yolanda Sanz, Roberto Edoardo Villa, Ruud Woutersen, Giovanna Martelli,Montserrat Anguita, Jaume Galobart, Jordi Ortúno, Joana Revez and Rosella Brozzi

Abstract
Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the efficacy of a product consisting of \textit{Limosilactobacillus reuteri} (formerly \textit{Lactobacillus reuteri}) DSM 32264 as a zootechnical additive for cats. The additive is a preparation of viable cells of \textit{L. reuteri} DSM 32264 and it has not been previously authorised as a feed additive in the European Union. The additive is intended for use in complete feed for cats at a minimum inclusion level of $6 \times 10^9$ colony forming units (CFU) per animal and day. In a previous opinion, the FEEDAP Panel could not conclude on the efficacy of \textit{L. reuteri} DSM 32264 for cats. The applicant has provided supplementary information to support the efficacy of the additive for cats. Based on the data provided, the FEEDAP Panel concluded that \textit{L. reuteri} DSM 32264 has the potential to improve faecal consistency by reducing the moisture content of stools from cats receiving the additive at $1 \times 10^{10}$ CFU/kg feed. However, the Panel had some reservations on the effects in the moisture content, which if maintained overtime, might cast doubts on the benefits on the long-term use of the additive since it could lead to constipation.

© 2022 Wiley-VCH Verlag GmbH & Co. KgaA on behalf of the European Food Safety Authority.

Keywords: zootechnical additives, gut flora stabilisers, \textit{Limosilactobacillus reuteri} DSM 32264, cats, efficacy, NBF-2

Requestor: European Commission

Question number: EFSA-Q-2021-00633

Correspondence: feedap@efsa.europa.eu
Panel members: Vasileios Bampidis, Giovanna Azimonti, Maria de Lourdes Bastos, Henrik Christensen, Birgit Dusemund, Mojca Fasmon Durjava, Maryline Kouba, Marta López-Alonso, Secundino López Puente, Francesca Marcon, Baltasar Mayo, Alena Pechová, Mariana Petkova, Fernando Ramos, Yolanda Sanz, Roberto Edoardo Villa and Ruud Woutersen.

Declarations of interest: If you wish to access the declaration of interests of any expert contributing to an EFSA scientific assessment, please contact interestmanagement@efsa.europa.eu.

Suggested citation: EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), Bampidis V, Azimonti G, Bastos ML, Christensen H, Dusemund B, Fasmon Durjava M, Kouba M, López-Alonso M, López Puente S, Marcon F, Mayo B, Pechová A, Petkova M, Ramos F, Sanz Y, Villa RE, Woutersen R, Martelli G, Anguita M, Galobart J, Ortuño J, Revez J and Brozzi R, 2022. Scientific Opinion on the safety and efficacy of a feed additive consisting of Limosilactobacillus reuteri (formerly Lactobacillus reuteri) DSM 32264 as a feed additive for cats (NBF Lanes s.r.l.). EFSA Journal 2022;20(8):7437, 7 pp. https://doi.org/10.2903/j.efsa.2022.7437

ISSN: 1831-4732

© 2022 Wiley-VCH Verlag GmbH & Co. KgaA on behalf of the European Food Safety Authority.

This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

The EFSA Journal is a publication of the European Food Safety Authority, a European agency funded by the European Union.
Table of contents

Abstract

1. Introduction
   1.1. Background and Terms of Reference as provided by the requestor
   1.2. Additional information

2. Data and methodologies
   2.1. Data
   2.2. Methodologies

3. Assessment

4. Conclusions

5. Documentation provided to EFSA/Chronology

References

Abbreviations

---

**Abstract**

---

1. **Introduction**

   1.1. Background and Terms of Reference as provided by the requestor
   1.2. Additional information

2. **Data and methodologies**

   2.1. Data
   2.2. Methodologies

3. **Assessment**

4. **Conclusions**

5. **Documentation provided to EFSA/Chronology**

**References**

**Abbreviations**

---

**Limosilactobacillus reuteri DSM 32264 for cats**

www.efsa.europa.eu/efsajournal 3 EFSA Journal 2022;20(8):7437
1. Introduction

1.1. Background and Terms of Reference as provided by the requestor

Regulation (EC) No 1831/2003 establishes the rules governing the Community authorisation of additives for use in animal nutrition and, in particular, Article 9 thereof defines the terms of the authorisation by the Commission.

The applicant NBF Lanes s.r.l., is seeking a Community authorisation of *Lactobacillus reuteri* DSM 32264 as a feed additive to be used as a gut flora stabiliser for cats (Table 1).

| Table 1: Description of the substances |
|---------------------------------------|
| **Category of additive** | **Zootechnical additives** |
| Functional group of additive | Gut flora stabilisers |
| Description | *Lactobacillus reuteri* DSM 32264 |
| Target animal category | Cats |
| Applicant | NBF Lanes s.r.l. |
| Type of request | New opinion |

On 27 November 2018, the Panel on Additives and Products or Substances used in Animal Feed of the European Food Safety Authority (‘EFSA’), in its opinion on the safety and efficacy of the product, could not conclude on the efficacy of *Lactobacillus reuteri* DSM 32264 in cats.

The Commission gave the possibility to the applicant to submit supplementary information and data in order to complete the assessment and to allow a revision of the EFSA’s opinion. The new data have been received on 18 February 2021 and the applicant has been requested to transmit them to EFSA as well.

In view of the above, the Commission asks EFSA to deliver a new opinion on *Lactobacillus reuteri* DSM 32264 as a feed additive for cats based on the supplementary data submitted by the applicant, in accordance with Article 29(1)(a) of Regulation (EC) No 178/2002.

1.2. Additional information

The additive is a preparation containing viable cells of *L. reuteri* DSM 32264. It has not been previously authorised as a feed additive in the European Union.

EFSA issued one opinion on the safety and efficacy of this product when used in feed for cats (EFSA FEEDAP Panel, 2019).

2. Data and methodologies

2.1. Data

The present assessment is based on data submitted by the applicant in the form of a supplementary information\(^2\) to a previous technical dossier on the same product.\(^3\)

In accordance with Article 38 of the Regulation (EC) No 178/2002\(^4\) and taking into account the protection of confidential information and of personal data in accordance with Articles 39 to 39e of the same Regulation, and of the Decision of EFSA’s Executive Director laying down practical arrangements concerning transparency and confidentiality,\(^5\) a non-confidential version of the supplementary information has been published on Open.EFSA.\(^6\)

---

1. The request refers to the synonym *Lactobacillus reuteri*, corresponding to the current taxonomic unit of *Limosilactobacillus reuteri*.
2. FEED dossier reference: EFSA-Q-2021-00663.
3. FEED dossier reference: FAD-2017-0002.
4. Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety. OJ L 31, 1.2.2002, p. 1–48.
5. Decision available online: https://www.efsa.europa.eu/en/corporate-pubs/transparency-regulation-practical-arrangements
6. Available online: https://open.efsa.europa.eu/questions/EFSA-Q-2021-00633
2.2. Methodologies

The approach followed by the FEEDAP Panel to assess the safety and the efficacy of active substance (trade name of the product) is in line with the principles laid down in Regulation (EC) No 429/20087 and the relevant guidance document: Guidance on the assessment of the efficacy of feed additives (EFSA FEEDAP Panel, 2018).

3. Assessment

The additive is a preparation of viable cells of *L. reuteri* DSM 32264 intended for use as a zootechnical additive (functional group: gut flora stabilisers) in feed for cats to exert beneficial effects in their gastrointestinal tract leading to an increase in faecal consistency. Since the last opinion of the FEEDAP Panel (EFSA FEEDAP Panel, 2019), the taxonomic unit of the species under assessment has been updated from the basionym *Lactobacillus reuteri* to *Limosilactobacillus reuteri* (Zheng et al., 2020) and considered in the list of QPS-recommended biological agents (EFSA BIOHAZ Panel, 2020). The current taxonomic unit is used hereafter in the opinion.

The additive is intended for use in complete and complementary feed for cats (with a moisture content < 14%) at a daily dose of 6 \( \times 10^9 \) CFU/animal, which would approximately equate to a range from 0.6–4.5 \( \times 10^{11} \) CFU/kg complete feed for cats.

In a previous opinion (EFSA FEEDAP Panel, 2019), the FEEDAP Panel could not conclude on the efficacy of *L. reuteri* DSM 32264 for cats, as none of the five efficacy studies could be further considered due to weaknesses in the experimental design and/or reporting. The applicant has provided supplementary information to support the efficacy of the additive.

A total of three trials with cats sharing a common design were submitted. The details on the study design are provided in Table 2 and the main results in Table 3. The studies were conducted with adult cats of both sexes and of different breeds (Chartreux, Persian and Scottish Fold cat) and body weight (BW), fed with a commercial dry extruded food once a day based on their maintenance energy requirements. Cats were daily examined by a veterinarian.

For each study, cats were acclimatised to individual housing for 14 days before the start of the study, during this period they received unsupplemented feed. At the study start, cats were randomly allocated to the two dietary treatments: control and *L. reuteri* DSM 32264 at 1 \( \times 10^{10} \) CFU/kg feed (not confirmed by analysis).\(^8\) The additive was mixed with the food using a maltodextrin carrier before consumption. Control animals received the same carrier without the additive.

Feed intake was measured daily. BW and body condition score (BCS) were recorded at days 0, 7, 14, 21, 28 and 35. BCS assessment was carried out by visual examination and palpation of the animal (nine points scale). On the same days, faecal samples were collected and assessed for moisture content (FM) and consistency (faecal score (FS), using a 7-point scoring scale: 1 = very hard and dry, 7 = watery). In addition, microbiological analyses (enumeration of lactobacilli and *Escherichia coli*/coliforms) were performed on the samples collected at days 0, 7, 21 and 35. However, details on the analytical methodology for the enumeration of *Escherichia coli*/coliforms were not provided despite the request.\(^8\)

According to the information provided, the statistical analysis of the data was done using a repeated measurements model and means were compared with a t-test.

### Table 2: Design of the efficacy trials performed in cats

| Trial | Total no of animals \((\text{animals} \times \text{gender} \times \text{treatment})\) | Breed, age and mean body weight \((\text{duration})\) |
|-------|-----------------------------------------------------------------|---------------------------------------------------|
| 1\(^8\) | 16 (Control: 4♂, 4♀; Treatment: 2♂, 6♀) | Chartreux (40 months old, 4 kg (35 days)) |
| 2\(^10\) | 12 (Control: 3♂, 3♀; Treatment: 1♂, 5♀) | Persian, 43 months old, 4 kg (35 days) |
| 3\(^11\) | 10 (Control: 2♂, 3♀; Treatment: 3♂, 2♀) | Scottish Fold, 40 months old, 3.8 kg (35 days) |

---

7 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC) No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
8 Technical dossier/Supplementary Information April 2022.
9 Technical dossier/Efficacy study_Certosino cats/Supplementary Information April 2022.
10 Technical dossier/Efficacy study_Persian cats/Supplementary Information April 2022.
11 Technical dossier/Efficacy study_Scottish cats/Supplementary Information April 2022.
Cats were healthy during the study. BW and BCS of cats did not change over time, and there were no differences between groups. Overall results showed a lower FM and FS in treated cats compared to control. For FM, a significant decrease was observed in all trials from day 21 onwards. Regarding the FS, a significant decrease of the scoring was observed from day 28 onwards in studies 1 and 2 but only in the overall value (average of all sampling days) in study 3. The Panel notes that the FM in the treated cats decreased linearly over time, with limited variability, and reaching considerably low values. Should this linear decrease in moisture content be extended/maintained with the prolonged use of the additive, it might lead to constipation, questioning the benefits of its use in cats.

### Table 3: Effects of *L. reuteri* DSM 32264 on faecal moisture and faecal score of stools from cats

| Faecal parameter | Moisture (g/g) | Consistency (seven-point score) |
|------------------|---------------|---------------------------------|
|                  | Trial 1       | Trial 2                        | Trial 3                   | Trial 1       | Trial 2                        | Trial 3                   |
| Treatment (CFU/kg feed) | 0 10^10 | 0 10^10 | 0 10^10 | 0 10^10 | 0 10^10 | 0 10^10 |
| Day              |              |                                 |                             |              |                                 |                             |
| 0                | 0.46         | 0.46                            | 0.45                        | 0.46         | 0.47                            | 0.48                        |
| 7                | 0.45         | 0.45                            | 0.45                        | 0.46         | 0.46                            | 0.46                        |
| 14               | 0.45         | 0.45                            | 0.44                        | 0.46         | 0.44                            | 0.44                        |
| 21               | 0.44         | 0.41*                           | 0.41*                       | 0.47         | 0.41*                           | 0.41*                       |
| 28               | 0.45         | 0.39*                           | 0.39*                       | 0.46         | 0.39*                           | 0.39*                       |
| 35               | 0.44         | 0.37*                           | 0.38*                       | 0.47         | 0.36*                           | 0.36*                       |
| Overall          | 0.45         | 0.41*                           | 0.41*                       | 0.46         | 0.42*                           | 0.42*                       |

*: Means in the same row within a trial are significantly different compared to control with p < 0.1.

Regarding the faecal microbiological analysis, in all studies at the end of the experimental period, lactobacilli counts were greater and *E. coli* counts lower in samples from animals receiving the additive compared to those from control animals. However, the FEEDAP Panel notes that this difference is marginal (< 1 log), and thus of questionable biological relevance.

### 4. Conclusions

The additive consisting of *L. reuteri* DSM 32264 has the potential to improve faecal consistency by reducing the moisture content of stools from cats receiving the additive at 10^10 CFU/kg feed. However, the Panel has some reservations on the linear decrease in the moisture content, which, if maintained over time, might cast doubts on the benefits on the long-term use of the additive since it could lead to constipation.

### 5. Documentation provided to EFSA/Chronology

| Date         | Event                                                                 |
|--------------|------------------------------------------------------------------------|
| 17/03/2021   | Dossier received by EFSA. *Lactobacillus reuteri* DSM 32264. Submitted by NBF Lanes s.r.l |
| 12/07/2021   | Reception mandate from the European Commission                           |
| 29/10/2021   | Application validated by EFSA – Start of the scientific assessment     |
| 04/02/2022   | Request of supplementary information to the applicant in line Article 7(3) of Commission Regulation (EC) No 1304/2003 – Scientific assessment suspended. *Issues: efficacy* |
| 13/04/2022   | Reception of supplementary information from the applicant - Scientific assessment re-started |
| 29/06/2022   | Opinion adopted by the FEEDAP Panel. End of the Scientific assessment  |
References

EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), Koutsoumanis K, Allende A, Alvarez-Ordóñez A, Bolton D, Bover-Cid S, Chemaly M, Davies R, De Cosare A, Hilbert F, Lindqvist R, Nauta M, Peixe L, Ru G, Simmons M, Skandamis P, Suffredini E, Coconcelli PS, Fernández Escámez PS, Maradona MP, Querol A, Suarez JE, Sundh I, Vlak J, Barizzone F, Hempen M and Herman L, 2020. Statement on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 12: suitability of taxonomic units notified to EFSA until March 2020. EFSA Journal 2020;18(7):6174, 42 pp. https://doi.org/10.2903/j.efsa.2020.6174

EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), Rychen G, Aquilina G, Azimonti G, Bampidis V, Bastos ML, Bories G, Chesson A, Coconcelli PS, Flachowsky G, Gropp J, Kolar B, Kouba M, López-Alonso M, López Puente S, Mantovani A, Mayo B, Ramos F, Saarela M, Villa RE, Wallace RJ, Wester P, Anguita M, Galobart J, Innocenti ML and Martino L, 2018. Guidance on the assessment of the efficacy of feed additives. EFSA Journal 2018;16(5):5274, 25 pp. https://doi.org/10.2903/j.efsa.2018.5274

EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), Bampidis V, Azimonti G, Bastos ML, Christensen H, Dusemund B, Kouba M, Kos Durjava M, López-Alonso M, López Puente S, Marcon F, Mayo B, Pechová A, Petkova M, Ramos F, Sanz Y, Villa RE, Woutersen R, Chesson A, Coconcelli PS, Wallace RJ, Rychen G, Brozzi R and Saarela M, 2019. Scientific Opinion on the safety and efficacy of Lactobacillus reuteri NBF-2 (DSM 32264) as a feed additive for cats. EFSA Journal 2019;17(1):5526, 10 pp. https://doi.org/10.2903/j.efsa.2019.5526

Zheng J, Wittouck S, Salvetti E, Franz C, Harris H, Mattarelli P, O’Toole P, Pot B, Vandamme P, Walter J, Watanabe KS, Felis G, Gänzle M and Lebeer S, 2020. A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. International Journal of Systematic and Evolutionary Microbiology, 70, 2782–2858. https://doi.org/10.1099/ijsem.0.004107

Abbreviations

| Abbreviation | Description                    |
|--------------|--------------------------------|
| BCS          | body condition score           |
| BW           | body weight                    |
| CFU          | colony forming unit            |
| FM           | faecal moisture                |
| FS           | faecal score                   |
| FEEDAP       | EFSA Scientific Panel on Additives and Products or Substances used in Animal Feed |